Cargando…

The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction

Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR). Our approach was the novel use of [Leu(27)]IGF-II, a human IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal growth-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Charnock, Jayne C., Dilworth, Mark R., Aplin, John D., Sibley, Colin P., Westwood, Melissa, Crocker, Ian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Physiological Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675800/
https://www.ncbi.nlm.nih.gov/pubmed/26530156
http://dx.doi.org/10.1152/ajpendo.00379.2015
_version_ 1782405063338098688
author Charnock, Jayne C.
Dilworth, Mark R.
Aplin, John D.
Sibley, Colin P.
Westwood, Melissa
Crocker, Ian P.
author_facet Charnock, Jayne C.
Dilworth, Mark R.
Aplin, John D.
Sibley, Colin P.
Westwood, Melissa
Crocker, Ian P.
author_sort Charnock, Jayne C.
collection PubMed
description Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR). Our approach was the novel use of [Leu(27)]IGF-II, a human IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal growth-restricted (FGR) mice. We hypothesized that the impact of [Leu(27)]IGF-II infusion in C57BL/6J (wild-type) and endothelial nitric oxide synthase knockout (eNOS(−/−); FGR) mice would be to enhance fetal growth and investigated this from mid- to late gestation; 1 mg·kg(−1)·day(−1) [Leu(27)]IGF-II was delivered via a subcutaneous miniosmotic pump from E12.5 to E18.5. Fetal and placental weights recorded at E18.5 were used to generate frequency distribution curves; fetuses <5th centile were deemed growth restricted. Placentas were harvested for immunohistochemical analysis of the IGF system, and maternal serum was collected for measurement of exogenously administered IGF-II. In WT pregnancies, [Leu(27)]IGF-II treatment halved the number of FGR fetuses, reduced fetal(P = 0.028) and placental weight variations (P = 0.0032), and increased the numbers of pups close to the mean fetal weight (131 vs. 112 pups within 1 SD). Mixed-model analysis confirmed litter size to be negatively correlated with fetal and placental weight and showed that [Leu(27)]IGF-II preferentially improved fetal weight in the largest litters, as defined by number. Unidirectional (14C)MeAIB transfer per gram placenta (System A amino acid transporter activity) was inversely correlated with fetal weight in [Leu(27)]IGF-II-treated WT animals (P < 0.01). In eNOS(−/−) mice, [Leu(27)]IGF-II reduced the number of FGR fetuses(1 vs. 5 in the untreated group). The observed reduction in FGR pup numbers in both C57 and eNOS(−/−) litters suggests the use of this analog as a means of standardizing and rescuing fetal growth, preferentially in the smallest offspring.
format Online
Article
Text
id pubmed-4675800
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Physiological Society
record_format MEDLINE/PubMed
spelling pubmed-46758002015-12-21 The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction Charnock, Jayne C. Dilworth, Mark R. Aplin, John D. Sibley, Colin P. Westwood, Melissa Crocker, Ian P. Am J Physiol Endocrinol Metab Articles Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR). Our approach was the novel use of [Leu(27)]IGF-II, a human IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal growth-restricted (FGR) mice. We hypothesized that the impact of [Leu(27)]IGF-II infusion in C57BL/6J (wild-type) and endothelial nitric oxide synthase knockout (eNOS(−/−); FGR) mice would be to enhance fetal growth and investigated this from mid- to late gestation; 1 mg·kg(−1)·day(−1) [Leu(27)]IGF-II was delivered via a subcutaneous miniosmotic pump from E12.5 to E18.5. Fetal and placental weights recorded at E18.5 were used to generate frequency distribution curves; fetuses <5th centile were deemed growth restricted. Placentas were harvested for immunohistochemical analysis of the IGF system, and maternal serum was collected for measurement of exogenously administered IGF-II. In WT pregnancies, [Leu(27)]IGF-II treatment halved the number of FGR fetuses, reduced fetal(P = 0.028) and placental weight variations (P = 0.0032), and increased the numbers of pups close to the mean fetal weight (131 vs. 112 pups within 1 SD). Mixed-model analysis confirmed litter size to be negatively correlated with fetal and placental weight and showed that [Leu(27)]IGF-II preferentially improved fetal weight in the largest litters, as defined by number. Unidirectional (14C)MeAIB transfer per gram placenta (System A amino acid transporter activity) was inversely correlated with fetal weight in [Leu(27)]IGF-II-treated WT animals (P < 0.01). In eNOS(−/−) mice, [Leu(27)]IGF-II reduced the number of FGR fetuses(1 vs. 5 in the untreated group). The observed reduction in FGR pup numbers in both C57 and eNOS(−/−) litters suggests the use of this analog as a means of standardizing and rescuing fetal growth, preferentially in the smallest offspring. American Physiological Society 2015-11-03 2016-01-01 /pmc/articles/PMC4675800/ /pubmed/26530156 http://dx.doi.org/10.1152/ajpendo.00379.2015 Text en Copyright © 2016 the American Physiological Society http://creativecommons.org/licenses/by/3.0/deed.en_US Licensed under Creative Commons Attribution CC-BY 3.0 (http://creativecommons.org/licenses/by/3.0/deed.en_US) : © the American Physiological Society.
spellingShingle Articles
Charnock, Jayne C.
Dilworth, Mark R.
Aplin, John D.
Sibley, Colin P.
Westwood, Melissa
Crocker, Ian P.
The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title_full The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title_fullStr The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title_full_unstemmed The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title_short The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
title_sort impact of a human igf-ii analog ([leu(27)]igf-ii) on fetal growth in a mouse model of fetal growth restriction
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675800/
https://www.ncbi.nlm.nih.gov/pubmed/26530156
http://dx.doi.org/10.1152/ajpendo.00379.2015
work_keys_str_mv AT charnockjaynec theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT dilworthmarkr theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT aplinjohnd theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT sibleycolinp theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT westwoodmelissa theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT crockerianp theimpactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT charnockjaynec impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT dilworthmarkr impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT aplinjohnd impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT sibleycolinp impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT westwoodmelissa impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction
AT crockerianp impactofahumanigfiianalogleu27igfiionfetalgrowthinamousemodeloffetalgrowthrestriction